Platelet-released growth factors inhibit proliferation of primary keratinocytes in vitro

Ann Anat. 2018 Jan:215:1-7. doi: 10.1016/j.aanat.2017.09.002. Epub 2017 Sep 18.

Abstract

Autologous thrombocyte concentrate lysates as platelet-released growth factors (PRGF) or Vivostat Platelet Rich Fibrin (PRF®) represent important tools in modern wound therapy, especially in the treatment of chronic, hard-to-heal or infected wounds. Nevertheless, underlying cellular and molecular mechanisms of the beneficial clinical effects of a local wound therapy with autologous thrombocyte concentrate lysates are poorly understood. Recently, we have demonstrated that PRGF induces antimicrobial peptides in primary keratinocytes and accelerates keratinocytes' differentiation. In the present study we analyzed the influence of PRGF on primary human keratinocytes' proliferation. Using the molecular proliferation marker Ki-67 we observed a concentration- and time dependent inhibition of Ki-67 gene expression in PRGF treated primary keratinocytes. These effects were independent from the EGFR- and the IL-6-R pathway. Inhibition of primary keratinocytes' proliferation by PRGF treatment was confirmed in colorimetric cell proliferation assays. Together, these data indicate that the clinically observed positive effects of autologous thrombocytes concentrates in the treatment of chronic, hard-to-heal wounds are not based on an increased keratinocytes proliferation.

Keywords: Keratinocytes; Platelet-released growth factors; Proliferation; Wound healing.

MeSH terms

  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Humans
  • Intercellular Signaling Peptides and Proteins / pharmacology*
  • Keratinocytes / drug effects*
  • Platelet-Rich Plasma*
  • Wound Healing

Substances

  • Intercellular Signaling Peptides and Proteins